Evidence map›Paper›PMID 42767999›Full record

ArticleNature communications2026

Directed evolution of an enantiocomplementary S

Thomas M Lister, George W Roberts, Cristina Duran, Guillem Casadevall, Fei Zhao, Alexander A V Millman, Igor Larrosa, Sílvia Osuna, Anthony P Green

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thomas M ListerManchester Institute of Biotechnology, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-6677-2797
George W Roberts *Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.
Cristina Duran *Institut de Química Computacional i Catàlisi (IQCC) and Departament de Química, Universitat de Girona, Girona, Spain.ORCID http://orcid.org/0000-0003-3094-8823
Guillem CasadevallInstitut de Química Computacional i Catàlisi (IQCC) and Departament de Química, Universitat de Girona, Girona, Spain.ORCID http://orcid.org/0000-0003-4442-1600
Fei ZhaoManchester Institute of Biotechnology, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0003-1841-4466
Alexander A V MillmanDepartment of Chemistry, School of Natural Science, The University of Manchester, Manchester, UK.
Igor LarrosaDepartment of Chemistry, School of Natural Science, The University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-5391-7424
Sílvia OsunaInstitut de Química Computacional i Catàlisi (IQCC) and Departament de Química, Universitat de Girona, Girona, Spain. silvia.osuna@udg.edu.ORCID http://orcid.org/0000-0003-3657-6469
Anthony P GreenManchester Institute of Biotechnology, The University of Manchester, Manchester, UK. Anthony.green@manchester.ac.uk.ORCID http://orcid.org/0000-0003-0454-1798

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101088032EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 101158166EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 833337EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) ERC-2022-CoG-101088032Generalitat de Catalunya (Government of Catalonia) SGR 2021 00487Human Frontier Science Program (HFSP) RGP0004/2022RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/M017702/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/W014483/1RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/R00661X/1RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/S01778X/1RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/S023755/1RCUK | Engineering and Physical Sciences Research Council (EPSRC) EP/Z531157/1
6 · The paper itself

Abstract

Enzymes that catalyze non-natural C-C bond-forming reactions are powerful tools in asymmetric synthesis, yet reprogramming their active sites to invert stereochemical outcome remains challenging. Building on our recently engineered S

Indexed as

Directed Molecular EvolutionBiocatalysisCatalysisCatalytic DomainModels, MolecularStereoisomerismSubstrate Specificity

Identifiers

PMID42767999
PMCPMC13594109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.